A Diagnostics & Imaging Week
iCAD (Nashua, New Hampshire), a provider of Computer Aided Detection (CAD) solutions to detect breast cancer, reported that it received a favorable arbitration decision on Case No. 13133Y00865, R2 Technology and Shih-Ping Wang vs. iCAD.
In this case, brought by R2 (Sunnyvale, California), an iCAD competitor, R2 alleged that iCAD infringed two of its patents. A panel of three arbitrators rejected all of R2's claims, finding that iCAD did not infringe any patent asserted by R2, the company said.
W. Scott Parr, iCAD's president and CEO, called the decision "a tremendous win" for iCAD and also "for the premise that computer-aided detection should be affordable and accessible to all women at risk of breast cancer."
In response to the arbitration commenced by R2, iCAD asserted in a counterclaim that R2 infringed several iCAD patents. The arbitrators found that R2 did not infringe on those patents.
iCAD offers a range of CAD systems, it says, for the high, mid and low volume mammography markets. It says it provides "the most frequently selected CAD solution for film-based and digital breast screening."